This archive contains the following articles listed by volume, issue and page number:
 |
|
|
Volume 22, 2018 Articles |
Title (Click for Details) |
Vol/Issue |
Page |
PreScription: 2017--Some Good Things Happened and Some Others |
Vol. 22 No. 1 |
4 |
Certification, Accreditation, and Credentialing for 503A Compounding Pharmacies |
Vol. 22 No. 1 |
7 |
Pain: Systematic Review of Pharmacy Compounding of Pain Medication |
Vol. 22 No. 1 |
19 |
The International Academy of Compounding Pharmacists: Government Affairs Lookback on 2017 Accomplishments and Look Ahead at 2018 Initiatives |
Vol. 22 No. 1 |
26 |
Basics of Compounding: Providing Pharmacy Services to Bariatric Surgery Patients |
Vol. 22 No. 1 |
30 |
Sterile Basics of Compounding: Relationship Between Syringe Size and Dosing Accuracy |
Vol. 22 No. 1 |
41 |
Calculations |
Vol. 22 No. 1 |
48 |
Glutamate and Aspartate Cardioplegia Additive Solution |
Vol. 22 No. 1 |
50 |
Mercaptopurine 50 mg/mL in Ora-Sweet and Ora-Plus Suspension |
Vol. 22 No. 1 |
51 |
Metronidazole 50 mg/mL in Ora-Blend Suspension |
Vol. 22 No. 1 |
52 |
Miconazole 10% in Recura Topical Cream |
Vol. 22 No. 1 |
53 |
Naproxen 25 mg/mL in Oral Mix or Oral Mix SF |
Vol. 22 No. 1 |
54 |
Penicillamine-D 50 mg/mL in SyrSpend SF pH4 Oral Suspension |
Vol. 22 No. 1 |
55 |
Ranitidine 15 mg/mL in SyrSpend SF pH4 |
Vol. 22 No. 1 |
56 |
Sodium Citrate 9% Nasal Spray for Olfactory Disorders |
Vol. 22 No. 1 |
57 |
Thalidomide 20 mg/mL in Ora-Plus and Ora-Sweet Suspension |
Vol. 22 No. 1 |
58 |
Voriconazole 40-mg/mL Oral Suspension |
Vol. 22 No. 1 |
59 |
Effects of Compounded Stanford Modified Oral Rinse (MucoLox) on the Survival and Migration of Oral Keratinocytes and Fibroblasts: Implications for Wound Healing |
Vol. 22 No. 1 |
60 |
Stability of an Alcohol-free, Dye-free Hydrocortisone (2 mg/mL) Compounded Oral Suspension |
Vol. 22 No. 1 |
66 |
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Injection and Dexamethasone Sodium Phosphate Injection |
Vol. 22 No. 1 |
76 |
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride |
Vol. 22 No. 1 |
86 |
PreScription: Drug Quality and Security Act Implementation Subcommittee Hearing |
Vol. 22 No. 2 |
92 |
Pharmacogenomics: Precision Pharmacy in 503A Compounding |
Vol. 22 No. 2 |
95 |
Personalized Medicine and Customized Drug Delivery Systems: The New Trend of Drug Delivery and Disease Management |
Vol. 22 No. 2 |
108 |
IACP Legislative/Regulatory Update: The International Academy of Compounding Pharmacists Testifies at U.S. House of Representatives' Energy & Commerce Health Subcommittee Pharmacy Compounding Hearing |
Vol. 22 No. 2 |
125 |
Quality Control: Lessons Learned from a Trimix Stability Study in a 503A Compounding Pharmacy |
Vol. 22 No. 2 |
129 |
Basics of Compounding: Compounding Microemulsions |
Vol. 22 No. 2 |
137 |
Calculations |
Vol. 22 No. 2 |
144 |
Clonidine Hydrochloride 10 mg/mL in Inorpha Solution |
Vol. 22 No. 2 |
146 |
Dorzolamide 2% and Timolol 0.5% Ophthalmic Solution |
Vol. 22 No. 2 |
147 |
Lamotrigine 1-mg/mL in SyrSpend SF pH4 Oral Suspension |
Vol. 22 No. 2 |
148 |
Levodopa and Carbidopa Rectal Suspension |
Vol. 22 No. 2 |
149 |
Prochlorperazine Edisylate 0.5% Nasal Spray |
Vol. 22 No. 2 |
150 |
Rolapitant Injectable Emulsion with Palonosetron Hydrochloride Admixture |
Vol. 22 No. 2 |
151 |
Spironolactone 5-mg/mL in Suspendit Oral Suspension |
Vol. 22 No. 2 |
152 |
Trilostane 5-mg/mL in Cod Liver Oil Suspension (Vet) |
Vol. 22 No. 2 |
153 |
Evaluation and Comparison of Wound Healing Properties of an Ointment (AlpaWash) Containing Brazilian Micronized Propolis and Peucedanum ostruthium Leaf Extract in Skin Ulcer in Rats |
Vol. 22 No. 2 |
154 |
The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions |
Vol. 22 No. 2 |
164 |
Topical Ketamine in the Treatment of Complex Regional Pain Syndrome |
Vol. 22 No. 2 |
172 |
PreScription: Influence and Sphere of Influence |
Vol. 22 No. 3 |
180 |
Pitch Ointment: Applications in Scar and Wound Management |
Vol. 22 No. 3 |
182 |
Establishing a Rationale for Compounding Hormone Replacement Therapy |
Vol. 22 No. 3 |
190 |
Case Report of a Human Papillomavirus Infection Treated with Green Tea Extract and Curcumin Vaginal Compounded Medications |
Vol. 22 No. 3 |
196 |
Your Presence is Needed at Compounders on Capitol Hill! |
Vol. 22 No. 3 |
204 |
Quality Control–Sterile Compounding: Analytical Methods. Density Determinations and Quality Control in Nonsterile and Sterile Compounding |
Vol. 22 No. 3 |
206 |
Basics of Compounding–Nonsterile: Compounding Self-emulsifying Drug Delivery Systems and Other Self-emulsifying Lipid Formulations, Part 1 |
Vol. 22 No. 3 |
220 |
Calculations |
Vol. 22 No. 3 |
230 |
Anhydrous Silicon Base Topical Gel Vehicle |
Vol. 22 No. 3 |
232 |
Atenolol 1 mg/mL or 5 mg/mL in SyrSpend SF pH4 |
Vol. 22 No. 3 |
233 |
Dorzolamide 2% Ophthalmic Solution |
Vol. 22 No. 3 |
234 |
Gabapentin 100 mg/mL in Oral Mix or Oral Mix SF Suspension |
Vol. 22 No. 3 |
235 |
Pyrimethamine 2 mg/mL in Ora-Plus and Ora-Sweet Oral Suspension |
Vol. 22 No. 3 |
236 |
Rolapitant Injectable Emulsion with Dexamethasone Sodium Phosphate Admixture |
Vol. 22 No. 3 |
237 |
Simvastatin 1 mg/mL in SyrSpend SF pH4 Oral Suspension |
Vol. 22 No. 3 |
238 |
Trimethoprim 20 mg/mL and Sulfadiazine 100 mg/mL in Suspendit Oral Suspension |
Vol. 22 No. 3 |
239 |
Investigation of the Physical, Chemical, and Microbiological Stability of Oral Solutions Compounded with Herbals |
Vol. 22 No. 3 |
240 |
Comparison of Rheological and Sedimentation Behavior of Commercially Available Suspending Vehicles for Oral Pharmaceutical Preparations |
Vol. 22 No. 3 |
247 |
The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia |
Vol. 22 No. 3 |
252 |
Trace Level Analysis of Airborne Hormone Particulates |
Vol. 22 No. 3 |
257 |
Erratum: Formulation: Lansoprazole 3-mg/mL Oral Suspension |
Vol. 22 No. 3 |
263 |
PreScription: Factors Related to Drug Waste and Pharmacy Solutions |
Vol. 22 No. 4 |
268 |
Compounded Low-dose Naltrexone for the Treatment of Guttate Psoriasis: A Case Report |
Vol. 22 No. 4 |
270 |
Compounding from a Pharmacy Student's Perspective |
Vol. 22 No. 4 |
281 |
The History, Symptoms, Causes, Risk Factors, Types, Diagnosis, Treatments, and Prevention of Gout, Part 1 |
Vol. 22 No. 4 |
284 |
Quality Control: Water Activity Considerations for Beyond-use Dates |
Vol. 22 No. 4 |
288 |
Basics of Compounding--Nonsterile: Compounding Self-emulsifying Drug Delivery Systems and Other Self-emulsifying Lipid Formulations, Part 2 |
Vol. 22 No. 4 |
294 |
Basics of Sterile Compounding: Criteria for Determining Beyond-use Dating |
Vol. 22 No. 4 |
303 |
Calculations |
Vol. 22 No. 4 |
314 |
Anhydrous Medium-chain Triglycerides Gel |
Vol. 22 No. 4 |
316 |
Budesonide 1-mg//10-mL Mucolox Oral Suspensions |
Vol. 22 No. 4 |
317 |
Cinacalcet 5-mg/mL in Oral-Plus/Ora-Sweet Suspension |
Vol. 22 No. 4 |
318 |
Ketoprofen 10% in Pluronic Lecithin Organogel |
Vol. 22 No. 4 |
319 |
Metronidazole Benzoate 70 mg/mL in SyrSpend SF Oral Suspension |
Vol. 22 No. 4 |
320 |
Midazolam 1 mg/mL in SyrSpend SF or SyrSpend SF Cherry |
Vol. 22 No. 4 |
321 |
Minoxidil 50 mg/mL in Espumil Foam Base |
Vol. 22 No. 4 |
322 |
Oseltamivir Phosphate 15 mg/mL in SyrSpend SF |
Vol. 22 No. 4 |
323 |
Pentoxifylline 5% in Dermabase |
Vol. 22 No. 4 |
324 |
Propranolol Hydrochloride 1 mg/mL in SyrSpend SF Oral Suspension |
Vol. 22 No. 4 |
325 |
Stability of Extemporaneously Prepared Sodium Benzoate Oral Suspension |
Vol. 22 No. 4 |
326 |
Kinetics of Tetracaine Solvolysis in Propylene Glycol |
Vol. 22 No. 4 |
329 |
Long-term Physicochemical Stability of Concentrated Solutions of Noradrenaline Bitartrate in Polypropylene Syringes for Administration in the Intensive Care Unit |
Vol. 22 No. 4 |
335 |
Comparative Stability of Vitamin K1 Oral Liquids Prepared in Sterile Water for Injection and Stored in Amber Glass Bottles and Amber Plastic Syringes |
Vol. 22 No. 4 |
340 |
Antineoplastic Drug Contamination on the Outside of Prepared Infusion Bags |
Vol. 22 No. 4 |
345 |
PreScription: Updating Formulations |
Vol. 22 No. 5 |
356 |
Current Trends and Emerging Priorities in Compounded Preparations for Children |
Vol. 22 No. 5 |
358 |
Certification of Powder-containment Hoods for Nonsterile Compounding |
Vol. 22 No. 5 |
369 |
Compounding Enclosures: Ensuring Safety During the Preparation of Sterile and Nonsterile Formulations |
Vol. 22 No. 5 |
387 |
Quality Assurance and Quality Control: Being Prepared for U.S. Food and Drug Administration Inspections and Staying in Compliance with United States Pharmacopeia Chapter <797>: Part 1 |
Vol. 22 No. 5 |
401 |
Calculations |
Vol. 22 No. 5 |
406 |
Cysteamine 0.5% Ophthalmic Solution |
Vol. 22 No. 5 |
408 |
Fluoxetine 50 mg/mL in Pluronic Lecithin Organogel |
Vol. 22 No. 5 |
409 |
Pergolide Mesylate 0.2-mg/mL Oral Liquid, Veterinary |
Vol. 22 No. 5 |
410 |
Torsemide 5 mg/mL in Ora-Plus:Ora-Sweet Suspension |
Vol. 22 No. 5 |
411 |
Stability of Tranexamic Acid Mouth Rinse |
Vol. 22 No. 5 |
412 |
Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags |
Vol. 22 No. 5 |
417 |
A Cold Process Preparation of Vetiveria zizanioides (L.) Nash Oil Lotions using Simulgel FL as an Emulsifier |
Vol. 22 No. 5 |
424 |
Formulation and Stability Study of Eslicarbazepine Acetate Oral Suspensions for Extemporaneous Compounding |
Vol. 22 No. 5 |
433 |
PreScription: Standardized Concentrations: Pro or Con? |
Vol. 22 No. 6 |
444 |
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications |
Vol. 22 No. 6 |
446 |
Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome |
Vol. 22 No. 6 |
456 |
Case Study: Absorption of Testosterone Cream via Scrotal Delivery |
Vol. 22 No. 6 |
466 |
Compounding from a Pharmacy Student's Perspective: Staying Competitive as a Compounding Pharmacy |
Vol. 22 No. 6 |
471 |
Basics of Sterile Compounding. Quality Assurance and Quality Control: Being Prepared for U.S. Food and Drug Administration Inspections and Staying in Compliance with United States Pharmacopeia Chapter <797>: Part 2
|
Vol. 22 No. 6 |
475 |
Basics of Compounding: Vehicles for Compounded Oral Liquid Medications: A Review |
Vol. 22 No. 6 |
480 |
Calculations |
Vol. 22 No. 6 |
490 |
Clonazepam 0.2 mg/mL in SyrSpend SF pH4 Oral Suspension |
Vol. 22 No. 6 |
492 |
Diltiazem Hydrochloride 12 mg/mL in SyrSpend SF pH4 Oral Suspension |
Vol. 22 No. 6 |
493 |
Enalapril Maleate 1 mg/mL in SyrSpend SF pH4 Oral Suspension |
Vol. 22 No. 6 |
494 |
Hydrocortisone 2 mg/mL in Inorpha Suspension |
Vol. 22 No. 6 |
495 |
Hydroxyurea 100 mg/mL in Ora-Plus:Ora-Sweet, Ora-Plus: Ora-Sweet SF, Ora-Blend or Oral-Blend SF Oral Suspensions |
Vol. 22 No. 6 |
496 |
Prednisone 5 mg/mL ir Oral Mix Suspension |
Vol. 22 No. 6 |
497 |
Gabapentin in Elastic Liposomes: Preparation, Characterization, Drug Release, and Penetration Through Porcine Skin |
Vol. 22 No. 6 |
498 |
Physical and Chemical Stability of Estriol 0.025% to 1% Vaginal Creams (VersaBase) |
Vol. 22 No. 6 |
504 |
Compounded Orodispersible Films with Natural Ingredients for Halitosis: A Clinical Experience |
Vol. 22 No. 6 |
512 |
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
|
Vol. 22 No. 6 |
516 |
Errata |
Vol. 22 No. 6 |
527 |